Home Positive Results Takeda Presents Updated Data from Phase 3b/4 PROPEL Study of ADYNOVATE Personalized...

Takeda Presents Updated Data from Phase 3b/4 PROPEL Study of ADYNOVATE Personalized Prophylaxis in Severe Hemophilia A

Updated Medical Results
Over shoulder portrait of young Middle-Eastern scientist looking at data charts while working on medical research in laboratory

Takeda Pharmaceuticals announced updated results from its phase 3/4 PROPEL clinical trial for ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), in Melbourne, Australia.

The PROPEL study is a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough activity Levels in subjects with severe hemophilia A. Eligible subjects had FVIII activity <1%, annualized bleed rate (ABR) ≥2, and transitioned from a previous SHP660 (ADYNOVATE) study or were 12–65 years old with ≥150 exposure days to plasma-derived or recombinant FVIII. After initial PK assessments, subjects were randomized to receive 12 months of PK-guided prophylaxis targeting FVIII trough levels of 1–3% (REF) or 8–12% (ELE) (1st 6 months: dose adjustment period). The primary outcome was the percent of subjects with a total ABR=0 (all bleeds) during the 2nd 6-month study period.

The updated results of the PROPEL study show that ADYNOVATE prophylaxis in severe hemophilia A patients may enhance a patient’s PK profile – by targeting FVIII trough levels of 8–12% (elevated prophylaxis arm, ELE) as compared with 1–3% (reference prophylaxis arm, REF). This represents a clinically meaningful trend towards more patients experiencing zero bleeds [62% ELE versus 42% REF, respectively; p=0.0545]. Patients randomized to the 8-12% target group also saw a reduced mean total annualized bleed rate (ABR); (1.6 ELE versus 3.6 REF, respectively) and a reduced mean spontaneous joint ABR (0.5 ELE versus 2.0 REF). The most common adverse reactions were headache, diarrhea, nausea and rash.

About Hemophilia A

Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood. Hemophilia A is more common than hemophilia B, and affects about 158,225 people, whereas hemophilia B affects about 31,247 people worldwide. Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.

About ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated

ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated temporarily replaces the missing coagulation factor VIII that is needed for effective hemostasis.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.